`BIB_374`

GLP-1 receptor agonists and melanoma/skin-cancer risk — 2024–2025 evidence synthesis: semaglutide REASSURING (HR 0.96 melanoma in UK CPRD; neutral in RCT meta-analyses); liraglutide has a numerically elevated but NS melanoma signal (LEADER RCT HR 2.59, 0.92–7.27, tracked in EMA RMP); class-level evidence neutral-to-protective in large observational data. Patient (BMI 30.4 + hypertension) meets NICE TA875 eligibility criteria. FILLS a gap in TASK11/TASK12: if GLP-1 therapy ever considered post-WLE, prescriber must know about confirmed melanoma; semaglutide preferred over liraglutide.

Evidence grade: B
Tier: 2 (Pradhan 2024 Diabetic Medicine UK CPRD as primary source; Silverii 2025 DOM m
Cited by tasks: 11, 12, 21, 24
Identifiers: PMC12232360 · DOI:10.1111/dme

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_374/findings.md (research corpus). This page is a short context summary — not individualised medical advice.